SDZ IMM 125

structure given in first source; a hydroxyethyl derivative of serine(8)-cyclosporine; inhibits proliferation and functions of lymphocytes

Also Known As:

SDZ IMM-125; SDZ-IMM-125; cyclosporin A, 2-(O-(2-hydroxyethyl)-D-serine)-; oxeclosporin

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 07/01/1995 - "In this multicentre, double-blind, placebo-controlled study, the efficacy and tolerability of 40, 100, 200 and 400 mg SDZ IMM 125 daily were studied in 59 patients with psoriasis. " 07/01/1995 - "Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis."
2.	Necrosis 04/01/2000 - "Our findings suggest that in rat hepatocyte cultures, SDZ IMM 125 is a specific inducer of apoptosis after short-term incubation, and this overlaps with necrosis after longer treatment periods. "